As an ATCG consultant, Dr. Levy collaborates with academic researchers, clinical innovators, and industry leaders to provide expert guidance on the clinical translation of early-stage treatments, regulatory pathways, clinical trial design/execution, and optimization of patient safety. His work bridges the gap between scientific innovation and real-world application, ensuring the successful development of transformative therapies for rare diseases.
With extensive experience as a physician-scientist, Dan Levy has spent the latter half of his career specializing in the clinical development of treatments for rare diseases. Dr. Levy led strategic planning and clinical trial execution of gene therapy treatments and served as an active participant in consortia across industry, academia, and regulatory bodies. His career began in academic medicine, then transitioned to Pfizer, and now consulting as the head of ATCG rare.
Experience within Pharma, 2011-2025
- Led Clinical Development Strategy and Execution: Directed the clinical development strategy for gene therapies at Pfizer, pioneering innovative treatment pathways
- Directed Late-Stage Development: Oversaw the strategic development of potential treatments for rare neurologic diseases
- Planned and executed Phase III Programs: Led Pfizer’s Phase III gene therapy program for Duchenne muscular dystrophy
- Conducted Clinical Diligence: Served as Team Lead for clinical due diligence of various business development opportunities in rare diseases, focusing on neurological and renal conditions
- Managed Cross-Functional Teams: Coordinated diverse teams to plan the late-stage development of therapies for conditions such as diabetic nephropathy and acute kidney injury
- Fostered Collaborative Consortia: Participated in consortia involving academic institutions, regulatory bodies, and pharmaceutical companies to advance shared clinical goals
- Contributed to Safety Oversight: Served on Pfizer’s Kidney Safety Council, contributing to the rigorous oversight of drug safety